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BACKGROUND: Asparagine–glycine–arginine–human tumour necrosis factor (NGR–hTNF) is a vascular targeting agent exploiting a
tumour-homing peptide (NGR) that selectively binds to aminopeptidase N/CD13, overexpressed on tumour blood vessels.
Significant preclinical synergy was shown between low doses of NGR-TNF and doxorubicin.
METHODS: The primary aim of this phase I trial was to verify the safety of low-dose NGR–hTNF combined with doxorubicin in treating
refractory/resistant solid tumours. Secondary objectives included pharmacokinetics (PKs), pharmacodynamics, and clinical activity.
In all 15 patients received NGR–hTNF (0.2–0.4–0.8–1.6mgm
 2) and doxorubicin (60–75mgm
 2), both given intravenously every
3 weeks.
RESULTS: No dose-limiting toxicity occurred and the combination was well tolerated. Around two cases of neutropenic fevers, lasting 2
days, and two cases of cardiac ejection-fraction drops, one asymptomatic and the other symptomatic, were registered. Only 11% of
the adverse events were related to NGR–hTNF and were short-lasting and mild-to-moderate in severity. There was no apparent PK
interaction and the shedding of soluble TNF-receptors did not increase to 0.8mgm
 2. One partial response (7%), at dose level
0.8mgm
 2, and 10 stable diseases (66%), lasting for a median duration of 5.6 months, were observed.
CONCLUSIONS: NGR–hTNF plus doxorubicin was administered safely and showed promising activity in patients pre-treated with
anthracyclines. The dose level of 0.8mgm
 2 NGR–hTNF plus doxorubicin 75mgm
 2 was selected for phase II development.
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Tumour necrosis factor-alpha (TNF-a) was originally identified for
its ability to induce apoptosis of tumour-associated endothelial
cells and massive haemorrhagic necrosis of transplanted solid
tumours (Carswell et al, 1975). Subsequent studies have shown
that TNF-a can rapidly alter endothelial permeability and
markedly decrease interstitial fluid pressure (Brett et al, 1989),
both of which are believed to be critical for drug uptake in
tumours. Disappointingly, early-stage clinical development using
recombinant human TNF-a (hTNF-a) was hampered by severe
systemic toxicity, the maximum tolerated dose being 10–50 times
lower than the estimated effective dose (Creaven et al, 1989; Gamm
et al, 1991).
To exploit a ligand-direct approach, asparagine–glycine–
arginine–human tumour necrosis factor (NGR–hTNF) has been
genetically engineered by coupling the N-terminus of hTNF-a with
the C-terminus of a tumour-homing NGR-peptide, which is a ligand
of the aminopeptidase N (CD13) overexpressed by endothelial cells
of newly formed human tumour blood vessels (Curnis et al, 2000;
Corti and Ponzoni, 2004). CD13 is a membrane-bound metallopro-
tease, and is thought to have an important role in chemokine
processing and tumour invasion, and therefore is considered an
attractive target for inhibiting angiogenesis. Recently, in a CD13-null
mice model it was shown that although aminopeptidase-N activity is
not essential for embryonic and foetal development, including de
novo blood vessel formation (i.e., vasculogenesis) and normal adult
function, it is crucial for the pathological development of new blood
vessels from existing blood vessels (i.e., angiogenesis) in disease
(Rangel et al,2 0 0 7 ) .
In preclinical models, murine NGR–TNF showed a biphasic
dose–response curve with significant anti-tumour activity even at
very low doses in the nanogram range (0.005mgkg
 1) (Curnis et al,
2002), equivalent in humans to a dose of 0.2mgm
 2, which is the
selected starting dose for phase I clinical development. Further-
more, it was shown that one mechanism underlying the synergism
displayed by the combination between minute doses of murine
NGR–TNF and doxorubicin was related to vascular barrier
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salteration and thus increased the uptake of this chemotherapeutic
agent in tumours (Curnis et al, 2002). It is to be noted that NGR–
TNF increased both the percentage of tumour cells that could be
reached by doxorubicin in 2h and the intracellular amount of the
drug, suggesting that NGR–TNF can alter drug-penetration
barriers. Moreover, the sequence of drugs and the timing of
administrations are crucial for these effects. In fact, the maximal
synergism was observed within a 2-h interval between the
administration of NGR–TNF and subsequent chemotherapy
dosing in all models and with all chemotherapeutics tested (Sacchi
et al, 2006).
Recently, the phase I dose-escalation study, exploring 17 dose
levels ranging from 0.2 to 60mgm
 2 in 70 patients, established the
maximum tolerated dose (MTD) of NGR–hTNF at 45mgm
 2,
when given as a single agent once every 3 weeks, with dose-limiting
toxicities at 60mgm
 2 being characterised by grade 3 dyspnoea
and acute infusion reaction (van Laarhoven et al, 2008).
In light of the promising preclinical findings, the present phase I
clinical trial was designed to determine a safe low dose of NGR–
hTNF in combination with the standard dose of doxorubicin.
PATIENTS AND METHODS
Eligibility criteria
The following inclusion criteria had to be met: age X18 years;
histologically or cytologically confirmed solid tumour not amen-
able to any clinical improvement by current standard treatments;
Eastern Cooperative Oncology Group (ECOG) performance status
p1; normal bone marrow, hepatic, and renal function; previous
treatment with a lifetime cumulative dose of anthracyclines
o300mgm
 2 (to allow the administration of an adequate number
of cycles). Patients were excluded if they had significant
cardiovascular disease, including a baseline cardiac ejection
fraction (EF) o55%, or known central nervous system (CNS)
metastases, as were patients who completed radiotherapy or
systemic therapy within 4 weeks or underwent surgery within 2
weeks of the start of NGR–hTNF treatment. All patients provided
written informed consent, and the protocol was approved by
institutional ethics review committees.
Study design and dosing
This was a multicentre, multinational, phase I dose-escalation
study with three patients who were administered each of four
sequentially increasing low-dose levels of NGR–hTNF (0.2–0.4–
0.8–1.6mgm
 2), given intravenously through a 1-h infusion every
3 weeks, in combination with a fixed dose of doxorubicin
(75mgm
 2), given through a 15-min intravenous infusion, 2 h
after the start of NGR–hTNF infusion. In the first cohort, NGR–
hTNF was given at the starting dose of 0.2mgm
 2 in combination
with a lower dose ( 20%) of doxorubicin (60mgm
 2). The
maximum cumulative dose of doxorubicin was capped at
550mgm
 2. Patients with continued clinical response or stable
disease were eligible to receive NGR–hTNF as a single agent until
progressive disease or unacceptable toxicity.
The primary objective was to verify the safety of low doses of
NGR–hTNF in combination with doxorubicin for the establish-
ment of presence or absence of dose-limiting toxicities (DLTs).
Secondary aims included a pharmacokinetic (PK) analysis of
NGR–hTNF and doxorubicin, monitoring of soluble TNF receptor
(sTNF-RI and sTNF-RII) levels, and preliminary anti-tumour
activity assessment.
Dose-limiting toxicities
Dose-limiting toxicities applicable to the study were defined as
adverse events occurring during the first cycle and fulfilling one of
the following criteria: any grade 3–4 non-haematological toxicity,
with the exclusion of alopecia, nausea, vomiting, and fever, which
could be rapidly controlled with appropriate measures; an absolute
neutrophil count (ANC) o500ml
 1 lasting for X7 days; a
neutropenic fever defined as ANCo1000ml
 1 and fever438.51C;
a thrombocytopenia p25000/ml or thrombocytopenic bleeding
requiring transfusion; and a severe hypotension requiring
dopamine administration.
A standard 3þ3 escalation design was followed. At each
dose level, the first patient had to complete one cycle before
subsequent patients could be included. To increase the dose
to the next dose level, the three patients enrolled at the previous
dose level had to complete the first cycle. To fully document the
safety profile, an expansion of the cohorts to six patients was
planned the presence of one DLT. Intolerable dosage was defined
as two or more out of six patients experiencing DLT and then the
immediate lower dose level was considered as the maximum
tolerated dose.
Pharmacokinetics and pharmacodynamics
Pharmacokinetic blood sampling was carried out on day 1 with
samples drawn before infusion and at 15, 30, 60, 90, and 120 (just
before doxorubicin administration), 134 (1min before the end of
doxorubicin administration), 180, 240, and 360min after the first
three cycles. NGR–hTNF and soluble plasma TNF receptors
(sTNF-RI and sTNF-RII) were computed by using an enzyme-
linked immunosorbent assay and values obtained at different time
points after each cycle were normalised by subtracting the time-
zero value. The bioanalytical assay of doxorubicin and its
metabolite doxorubicinol was carried out using liquid chromato-
graphy–tandem mass spectrometry. Maximum plasma concentra-
tion (Cmax) and area under the plasma concentration–time curve
to the last detectable concentration (AUC0 t last) were estimated
from plasma concentration–time data using the standard non-
compartmental methods.
Tumour assessment and safety
Tumour measurements were carried out at baseline and every 6
weeks until progressive disease. Measurable target lesions were
evaluated for response using Response Evaluation Criteria in Solid
Tumours (RECIST), and the duration of stable disease was
measured from the start of therapy until the criteria for
progression were met. Adverse events were recorded from day 1
till 28 days after the last dose, and were graded on the basis of the
Common Terminology Criteria for Adverse Events (CTCAEs),
version 3.0. Complete blood counts were assessed weekly while
patients were on therapy. Assessment of left ventricular ejection
fraction (LVEF) by echocardiogram was carried out before
treatment and every other cycle. Doxorubicin was planned to be
discontinued in patients who had experienced either a fall in LVEF
from baseline X20% or a fall to p45%.
RESULTS
Patients
A total of 15 patients (5 women and 10 men), with a median age of
58 years (range, 31–82 years) and a performance status of 0 (60%)
or 1 (40%), were enrolled between March 2006 and November
2006. All patients were heavily pre-treated: all had earlier received
chemotherapy (median of two regimens; range, 1–6), including
60% (n¼9) of the patients previously treated with an anthracy-
cline-containing regimen, 86% before surgery, and 40% before
radiotherapy.
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sSafety and tolerability
In total, 89 cycles of NGR–hTNF (median, 6; range, 2–15) and 62
cycles of doxorubicin (median, 4; range, 2–8) were administered.
According to the study protocol, six patients discontinued
doxorubicin when they reached the maximum cumulative dose
(i.e., 550mgm
 2). All patients received at least one dose of study
drugs and were assessable for toxicity.
No DLTs occurred and, as expected for this low-dose range of
NGR–hTNF, MTD was not reached. Globally, treatment disconti-
nuations were a result of progressive disease in 14 patients (93%)
and an adverse event (pulmonary embolism) in 1 patient (7%).
The majority of haematological (29%) and non-haematological
(71%) adverse events were mild (49%) to moderate (28%) in
severity, with grade 3 and 4 being observed in 15% and 8%,
respectively. The adverse events occurring in X20% of patients are
listed in Table 1 and the incidence of grade 3–4 toxicities by dose
levels and number of cycles is depicted in Figure 1.
The most commonly reported non-haematological adverse
events were nausea, asthenia, pain, and vomiting, and these were
mainly considered to be related to doxorubicin administration.
Haematological toxicity was assessed weekly throughout the
study. In all eight patients (all treated with doxorubicin
75mgm
 2) experienced grade 4 neutropenia in 17 cycles.
However, neutropenia was generally short-lasting and reversible.
There were only two neutropenic fever episodes, both occurring 2
weeks after the third cycle, lasting 2 days and recovering without
sequelae. Three patients required haematopoietic growth factor
support for neutropenia. A 20% dose reduction of doxorubicin was
required in four patients for 10 cycles and a dose delay was
registered in four patients for 7 cycles. No grade 4 anaemia or
thrombocytopenia occurred.
All patients underwent LVEF assessment by echocardiogram
every other cycle and the LVEF profile over time for all patients is
illustrated in Figure 2. The EF values changed in only 2 of 15
patients assessed. An asymptomatic drop in LVEF from 50% to
40% was observed in an 83-year-old patient after the fourth cycle
(lifetime cumulative doxorubicin dose of 500mgm
 2), with a
subsequent recovery to 60% recorded after two additional courses
of NGR–hTNF monotherapy and following doxorubicin disconti-
nuation. This patient, who was previously treated with liposomal
doxorubicin, also experienced a grade 3 febrile neutropenia after
the third cycle and was withdrawn from the study after the sixth
cycle owing to progressive disease. An additional symptomatic
drop in LVEF from 50% to 40% was registered in a 62-year-old
male patient with small-cell lung cancer and with a positive history
of hypertension and aortic aneurysm. He had been previously
treated with doxorubicin. After the fourth cycle (lifetime
cumulative doxorubicin dose of 400mgm
 2), he had progressive
disease and was hospitalised with a diagnosis of acute myocardial
Table 1 Haematological and non-haematological adverse events occurring in
X20% of patients or reaching grade 4 severity
Adverse event Any grade, n¼15 (%) Grade 1 n (%) Grade 2 n (%) Grade 3 n (%) Grade 4 n (%)
Haematological adverse events
Neutropenia 13 (86) — 2 (13) 3 (20) 8 (53)
Anemia 11 (73) 3 (20) 6 (40) 2 (13) —
Leukopenia 11 (73) — 3 (20) 5 (33) 3 (20)
Lymphopenia 5 (33) 1 (7) 1 (7) 2 (13) 1 (7)
Thrombocytopenia 2 (13) — 1 (7) 1 (7) —
Neutropenic fever 2 (13) — — 2 (13) —
Non-haematological adverse events
Nausea 12 (80) 10 (67) 2 (13) — —
Asthenia 10 (67) 6 (40) 3 (20) 1 (7) —
Pain 8 (53) 3 (20) 3 (20) 1 (7) 1 (7)
Vomiting 8 (53) 4 (27) 3 (20) 1 (7) —
Chills 7 (47) 3 (20) 4 (27) — —
Cough 5 (33) 4 (27) — 1 (7) —
Fever 5 (33) 4 (27) 1 (7) — —
Anorexia 5 (33) 3 (20) 1 (7) 1 (7)
Alopecia 5 (33) 4 (27) 1 (7) — —
Constipation 4 (27) 1 (7) 3 (20) — —
Mucositis 4 (27) 2 (13) 2 (13) — —
Insomnia 4 (27) 3 (20) 1 (7) — —
GGTP increase 3 (20) 1 (7) 1 (7) 1 (7)
Gastritis 3 (20) 1 (7) 2 (13) — —
Headache 3 (20) 1 (7) 2 (13) — —
Dysphagia 3 (20) 3 (20) — — —
AMI 1 (7) — — — 1 (7)
Pulmonary embolism 1 (7) — — — 1 (7)
Abbreviations: AMI, acute myocardial ischaemia; GGTP, gamma-glutamyl transferase.
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Figure 1 Incidence of grade 3–4 adverse events by dose levels. For each
dose level of asparagine–glycine–arginine–human tumour necrosis factor
(NGR-hTNF) and doxorubicin the following number of cycles were
administered, respectively: 0.2–60:12–12; 0.2–75:27–17; 0.4–75:13–
11; 0.8–75:25–12; 1.6–75:12–10.
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sischaemia. A coronarography revealed a thrombotic occlusion of
the left coronary artery treated with angioplasty and stent
placement. He was discharged after 3 weeks following an
improvement of his clinical conditions. In both patients, neither
anaemia nor other non-haematological toxicities of grade 3–4
were detected. Only 42 (11%) out of 390 adverse events were
considered to be related to NGR–hTNF. All of these events were of
mild (67%) to moderate (33%) intensity. About seven patients
(grade 1, n¼3; grade 2, n¼4) experienced rigors/chills in 15
cycles, and three patients (grade 1, n¼2; grade 2, n¼1)
experienced a transient blood pressure increase in 3 cycles. These
events seemed to be dose unrelated to, short-lasting, and presented
a clear temporal relationship between their onset and drug
infusion, as they generally occurred about 30–40min after the
start of infusion and lasted for approximately 30min.
Serum PKs and pharmacodynamics
The mean Cmax values of NGR–hTNF and AUC0 t last of
doxorubicin during the first three cycles for each dose level are
shown in Figures 3A and B. The average systemic exposure to
NGR–hTNF during cycles 2 and 3 was comparable to that found
during the first cycle and increased in a dose- and exposure-
proportionate manner. The mean (±s.d.) NGR–hTNF Cmax
achieved following the first cycle at doses of 0.2 (plus doxorubicin
60mgm
 2), 0.2 (plus doxorubicin 75mgm
 2), 0.4, 0.8, and
1.6mgm
 2 was 2.22 (±0.58), 1.82 (±0.90), 4.44 (±1.70), 8.10
(±1.70), and 15.70 (±1.34)pgml
 1, respectively.
The apparent terminal half-life (t1/2) of NGR–hTNF was
relatively short, with means±s.d. ranging from 0.99±0.83h (dose
level 0.2mgm
 2) to 2.56±0.65h (dose level 0.8mgm
 2). With the
exception of slightly more prolonged t1/2 values reported in the
present combination study, NGR–hTNF Pks were in reasonable
agreement with those found in a low-dose, single-agent phase I
study (Gallo-Stampino et al, 2007).
Consistently, doxorubicin systemic exposure was comparable
among the five cohorts of patients who received the dose of
60 or 75mgm
 2, irrespective of the NGR–hTNF dose given
in combination, and between cycles 2 and 3 vs cycle 1. Overall,
no apparent changes in the Pks of NGR–hTNF and
doxorubicin were detected by administering the two drugs in
combination.
During the first cycle of treatment at 0.2 and 0.4mgm
 2, both the
maximum (Emax) and the average (Eav) stimulatory effects
attributed to NGR–hTNF on the plasma levels of sTNF-RI were
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Figure 2 Left ventricular ejection fraction (LVEF) values over time for all
patients.
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Figure 3 Mean asparagine–glycine–arginine–human tumour necrosis factor (NGR-hTNF) Cmax (A) and doxorubicin AUC (B) during the first three
cycles by dose level. Mean plasma concentrations of soluble TNF receptors tumour necrosis factor receptor I (TNF-RI) (C) and tumour necrosis factor
receptor II (TNF-RII) (D) during the first cycle by dose level. Abbreviations: Cmax, maximal plasma concentration; AUC, area under the plasma concentration
vs time curve up to the last detectable concentration.
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sscattered around 0, indicating neither stimulation nor inhibition
effects of NGR–hTNF on the concentrations of the receptors. The
levels of the receptor were slightly above 0 at 0.8mgm
 2 dose,
whereas an increase was observed only at 1.6mgm
 2. For sTNF-
RII a similar behaviour was noted. However, at the highest dose
level tested (1.6mgm
 2), the stimulation of the concentrations of
sTNF-RII by NGR–hTNF was about two times higher than that of
sTNF-RI (Figures 3C and D). Moreover, at this dose level Emax for
both receptors was achieved around the time of attainment of
NGR–hTNF maximal plasma concentration. No circulating anti-
bodies to NGR–hTNF were detected.
Anti-tumour activity
One partial response was documented at the fourth dose level
(NGR–hTNF 0.8mgm
 2 þ doxorubicin 75mgm
 2) in a patient
with oesophageal cancer and lung metastases, who was previously
treated with two cisplatin- and fluorouracil-based regimens. An
unconfirmed partial response was registered after the sixth cycle in
an ovarian cancer patient who had previously received five
chemotherapy regimens. Stable disease as the best response was
reported in further 9 patients with a median duration of 5.6
months (Table 2). Off these patients with stable disease, the
maximum changes in their target lesions ranged from 40%
shrinkage to 9% growth (Figure 4A). Overall, the disease control
rate (partial response þ stable disease) in these patients who were
resistant to standard chemotherapy, including 9 patients who were
previously treated with an anthracycline-based regimen, was 73%
(11 out of 15 patients). Median progression-free survival for the
intent-to-treat patient population was 5.5 months, with some
patients experiencing progression-free durations longer than those
experienced while on the immediately previous regimen adminis-
tered (Figure 4B).
DISCUSSION
In the present study, no dose-limiting toxicities were observed and
the combination of low-dose NGR–hTNF with the standard-dose
doxorubicin was safe and well tolerated, without an apparent
Table 2 Anti tumour activity by dose levels
DL Pt. no.
Gender/age
(yrs)
Primary
tumour
Previous no.
of regimens
Previous
anthracyclines/
best response
NGR–TNF dose
(lgm
 2)/no. of
cycles
Doxorubicin
dose (mgm
 2)/
no. of cycles
Best
response
Duration of
PR or SD
(months)
1 1 M/58 Head and neck 2 No 0.2/4 60/4 SD 3
2 F/42 Cervix 6 No 0.2/6 60/6 SD 4.7
3 F/59 Colon 2 No 0.2/2 60/2 PD —
2 4 F/58 Ovarian 5 Yes/SD 0.2/8 75/5 SD
a 6.4
5 M/56 Ampulla of
Vater
1 No 0.2/15 75/8 SD 11.9
6 F/31 Thymoma 1 Yes/PD 0.2/4 75/4 SD 2.9
3 7 M/58 Thymoma 1 Yes/PD 0.4/3 75/3 PD
b —
8 M/62 SCLC 2 Yes/PD 0.4/4 75/4 SD 3.5
9 M/83 Angiosarcoma 3 Yes/PD 0.4/6 75/4 SD 4.2
4 10 M/59 Oesophageal 2 No 0.8/8 75/6 PR 4.7
11 M/54 Chordoma 5 Yes/PD 0.8/9 75/3 SD 8.2
12 F/54 Sarcoma 2 Yes
c 0.8/8 75/3 SD 6.5
5 13 M/51 Hepatocellular 1 Yes
d 1.6/8 75/6 SD 6.7
14 M/44 Melanoma 2 No 1.6/2 75/2 PD —
15 M/69 Sarcoma 2 Yes/PD 1.6/2 75/2 PD
b —
Abbreviations: DL, dose level; F, female; M, male; NGR–TNF, asparagine–glycine–arginine–tumour necrosis factor; PR, partial response; SCLC, small cell lung cancer,
PD, progressive disease; SD, stable disease.
aPatient with radiologically documented partial response after the sixth cycle.
bPatient with radiologically documented stable disease at
first tumour restaging carried out after two cycles.
cPatient treated with epirubicin in adjuvant setting.
dPatient with radiologically documented stable disease for whom epirubicin
treatment was stopped after two cycles because of marked increase of alpha-fetoprotein.
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sexacerbation of the well-known toxicity profile associated to
doxorubicin. In particular, NGR–hTNF did not appear to increase
the frequency or severity of doxorubicin-related cardiac toxicity as
measured by LVEF. Further analysis of this toxicity, however,
would necessitate longer treatment durations in a larger patient
population, monitoring of serial B-type natriuretic peptide and
troponin levels, and the assessment of QT interval prolongation
(Carver et al, 2007).
Moreover, only 11% of adverse events were considered to be
related to NGR–hTNF, and it should be noted that these events
were limited to manageable, short-lasting, and infusion time-
related constitutional symptoms.
The combination of molecularly targeted agents with che-
motherapy raises issues about the dose selection during early-stage
clinical development. Indeed, some of the guideposts in combining
chemotherapeutic agents (e.g., definition of MTD and avoidance of
overlapping toxicities) might not be suitable when combined with
biological agents that have low-toxicity profiles when used at the
low-dose range. Moreover, given their mainly cytostatic nature,
maximal anti-tumour activity could not necessarily coincide only
with MTD, but also with lower drug dose, that is, the optimal
biological dose (Kwak et al, 2007). Accordingly, the rationale of
this phase I study was based on a preclinical model showing that
even minute amounts of murine NGR–TNF were able to induce
synergistic anti-tumour activity in combination with doxorubicin,
mainly by damaging the tumour capillary network and increasing
the chemotherapeutic drug uptake in the tumour (Curnis et al,
2002).
Although not directly measured in this study, the anti-vascular
effects of NGR–hTNF have been previously observed by dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI) in the
dose-escalation phase I trial (van Laarhoven et al, 2008) and in an
additional single-agent phase I trial further exploring the low-dose
range (Gallo-Stampino et al, 2007) and, therefore, could be
considered supportive of the putative mechanism of synergism
shown by NGR–hTNF and doxorubicin. However, the synergism
of anti-vascular agents and chemotherapy could be alternatively
attributable simply to targeting two distinct cell populations
(Horsman and Siemann, 2006).
Notwithstanding the fact that optimal biological dose selection is
challenging, it is interesting to note that the aforementioned low-
dose single-agent phase I trial selected the dose of 0.8mgm
 2 for
further development, based on a more pronounced anti-vascular
effect observed at this dose and the lack of shedding of soluble
TNF-receptors registered up to this dose level. These soluble
receptors can compete for TNF-a with the cell-surface receptors,
thus blocking its bioavailability and activity, with the amount and
speed of receptor shedding being linearly correlated with the
serum TNF-a levels (Aderka et al, 1998). Similarly, no significant
shedding of circulating TNF-a receptors was observed up to the
dose of 0.8mgm
 2 in this study. Furthermore, patients enrolled in
this dose cohort experienced a low incidence of grade 3–4 toxicity
and promising disease control.
Even though anti-tumour activity was not a primary end point
of this study, the high disease control rate (73%) achieved in a
population heavily pre-treated with chemotherapy, including 9
patients (60%) with an anthracycline-based regimen, seem to be
promising by also taking into account the minimal toxicity profile
associated to NGR–hTNF and the apparent absence of overlapping
toxicity with doxorubicin.
In conclusion, the present phase I trial showed that the
combination of low-dose NGR-hTNF and standard-dose doxo-
rubicin is feasible, safe, and well tolerated when administered to
patients heavily pre-treated with chemotherapy, including anthra-
cyclines. The observed safety profile and anti-tumour activity
warrant further phase II clinical exploration of NGR–hTNF
0.8mgm
 2 and doxorubicin 75mgm
 2 in anthracycline-sensitive
solid tumours.
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